Clinical, Genetic, MR Spectroscopy characteristics and Response to Flunarizine in Episodic Ataxia Type 2: The Sheffield Ataxia Cohort
Episodic ataxia type 2 (EA2) is an autosomal-dominant calcium channelopathy caused by pathogenic mutations in the CACNA1A gene, characterized by episodic cerebellar symptoms and marked phenotypic heterogeneity. Data on real-world clinical features and treatment responses, particularly in the era of major genetic advances, remain limited. This is a retrospective observational single-centre case series of 58 individuals from 38 families with genetically confirmed EA2. Clinical, demographic, genetic, and treatment data were extracted from medical records using a standardized Excel-based data collection tool. Symptom patterns with associated neurological features, genetic characteristics, and treatment responses were analyzed descriptively. Paired MRI imaging including MR spectroscopy (MRS) of the cerebellum at baseline and follow up data, and medication efficacy were assessed using patient-reported benefit, and statistical analysis was performed using Wilcoxon signed rank test and Exact binomial testing respectively. The mean age at diagnosis was 35.2 ± 21.5 years, and a positive family history was identified in 48 patients (82.70%). The most frequent clinical manifestations were gait instability (87.93%), dysarthria (39.66%), headache (58.62%) and isolated dizziness (48.28%). Episodic symptoms predominated, with 33 patients (56.89%) experiencing discrete attacks. Amongst those with episodic symptoms, weekly attacks were the most common (42.4%), while 17 patients (29.31%) exhibited a non-episodic course with persistent symptoms. Interictal oculomotor abnormalities, including nystagmus, were noted in some individuals. Paired longitudinal MRS analyses for both vermis (W = 118.0, p = 0.67) and hemisphere (W = 122.0, p = 0.39) revealed no significant change over time. Flunarizine showed the highest rate of therapeutic benefit, with 76.5% of treated patients reporting improvement ( p = 0.04), whereas other treatments demonstrated variable but non-significant effects. This study highlights the clinical heterogeneity and neuroimaging (MRS) insight of EA2 underscoring the predominance of episodic manifestations, while also recognizing a subset with non-episodic symptoms. Flunarizine appears to be an effective, accessible therapeutic option for reducing attack frequency and duration in EA2, though further studies are required to compare efficacy with alternative therapeutic options such as acetazolamide.
Authors
- Priya Devi Shanmugarajah (ORCID: https://orcid.org/0000-0001-9252-9830)
- Vikrant Devgire
- Nigel Hoggard (ORCID: https://orcid.org/0000-0002-6447-7639)
- Marios Hadjivassiliou (ORCID: https://orcid.org/0000-0003-2542-8954)
- Ikechukwu Chukwuocha (ORCID: https://orcid.org/0009-0004-5058-1955)
- Nick J. Beauchamp
- Emma Foster (ORCID: https://orcid.org/0000-0002-2081-1973)
Institutions
- Royal Hallamshire Hospital (GB)
- Sheffield Children's NHS Foundation Trust (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- The Cerebellum
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1007/s12311-026-02122-y
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00